On September 26, 2019 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, reported that James F. Oliviero, President and Chief Executive Officer, will present a company overview at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019, at 11:15 a.m. EDT (Press release, Checkpoint Therapeutics, SEP 26, 2019, View Source [SID1234539815]). The conference will be held at the InterContinental New York Barclay Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Events page of the Investors & Media section of Checkpoint’s website: www.checkpointtx.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

On September 26, 2019 Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, reported that preclinical data defining the molecular mechanism for oncogenic activation of families of epidermal growth factor receptor (EGFR) allosteric mutations and showing activity of the Company’s lead product candidate BDTX-189 will be presented at the European Society for Medical Oncology Congress 2019, taking place from September 27 to October 1, 2019 in Barcelona, Spain (Press release, Black Diamond Therapeutics, SEP 26, 2019, View Source [SID1234539814]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Black Diamond’s presentation, entitled "Oncogenic Mutations at the Dimer Interface of EGFR Lead to Formation of Covalent Homo-dimers and Allosteric Activation of the Kinase Domain: A Mechanism Which Alters the Selectivity Profile of Oncogenic EGFR," will be presented Saturday, September 28, 2019 at 12:00 CEST, as part of the Developmental Therapeutics data session (Presentation 501P).

Elizabeth Buck, Ph.D., Co-Founder and Executive Vice President, Discovery and Translational Sciences said, "Despite clinical success with targeting EGFR ATP-site mutants, there are currently no drugs approved by the FDA to target allosteric EGFR mutations with a single therapy, including for patients with glioblastoma or lung cancer that express these mutations. Utilizing our Mutation-Allostery-Pharmacology, or MAP, platform, we defined the molecular mechanism for oncogenic activation of families of EGFR allosteric mutations and revealed how this mechanism decreases the efficacy of current generation of small molecule ATP-site inhibitors ineffective against these mutations."

"These preclinical data illustrate how BDTX-189, a novel ATP-site small molecule, selectively inhibits the activity of a broad range of allosteric EGFR and HER2 mutants, producing growth regression of allosteric EGFR mutant patient-derived tumors in vivo," added Dr. Buck.

MAP platform

Black Diamond’s Mutation-Allostery-Pharmacology (MAP) platform is built on three central pillars – discover, reveal, and target. The Company uses population-level cancer genetic data obtained from all tumor types to identify potential families of mutations that occur within individual oncogenes and rank the mutations for potential oncogenicity. Black Diamond then uses its MAP platform to understand the mechanism for oncogenic activation and its team of experienced medicinal chemists then develops mutation spectrum-selective drugs for the identified targets. Black Diamond’s MAP platform has generated a pipeline of orally available, potent and selective small molecule kinase inhibitors that target a range of driver mutations in cancer.

About BDTX-189

BDTX-189 is designed to be an orally available, irreversible small molecule inhibitor that targets undrugged oncogenic driver mutations of the ErbB kinases in epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). These include extracellular domain allosteric mutations of HER2, as well as EGFR and HER2 domain exon 20 insertions, and additional activating oncogenic drivers of ErbB. The ErbB receptors are a group of receptor tyrosine kinases involved in key cellular functions, including cell growth and survival. Currently, there are no medicines approved by the U.S. Food and Drug Administration to target all of these oncogenic mutations with a single therapy. Black Diamond Therapeutics is completing investigational new drug (IND)-enabling activities for BDTX-189 and plans to start a combined Phase 1/2 clinical trial in the first half of 2020.

On September 26, 2019 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") reported that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 1:15 p.m. ET in New York, NY (Press release, Aurinia Pharmaceuticals, SEP 26, 2019, View Source [SID1234539813]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of the presentation will also be archived on the Company website for thirty days following the event.

On September 26, 2019 Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, reported multiple data presentations at the upcoming American Academy of Ophthalmology (AAO) 2019 Annual Meeting, being held October 12-15, 2019 in San Francisco, CA (Press release, Aura Biosciences, SEP 26, 2019, View Source [SID1234539812]). Aura’s lead clinical asset, AU-011, will also be highlighted in presentations at related medical meetings taking place in San Francisco around AAO 2019, including the Ophthalmology Innovation Summit taking place October 10, 2019, and the American Association of Ophthalmic Oncologists and Pathologists (AAOOP) 2019 Annual Meeting taking place October 13, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Two key presentations at the AAO meeting include study updates by key opinion leaders Dr. Jay S. Duker, Director New England Eye Center, Professor and Chair Tufts Medical Center and Dr. Amy C. Schefler, Weill Cornell Medical College and Retina Consultants of Houston, which will include updated clinical data from Aura’s ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma. An additional presentation will be given at AAOOP 2019 by Dr. Abdhish Bhavsar, Board Certified Ophthalmologist at The Retina Center and an investigator for Aura’s Phase 1b/2 clinical trial.

"There are no FDA approved therapies for the treatment of choroidal melanoma, the most common type of primary eye cancer," said Cadmus Rich, MD, Chief Medical Officer of Aura Biosciences. "Patients are currently treated with radiotherapy and surgery which typically results in severe vision loss, along with many other significant adverse effects and comorbidities. If approved, AU-011 will be the first targeted therapy for the treatment of choroidal melanoma, with the potential to not only provide tumor control, but also preserve vision. We are excited to have these presentations on our AU-011 program and we look forward to sharing our novel technology, clinical data and an update on new delivery methods for AU-011 with the ophthalmology community at AAO and the accompanying events this year."

The details for the AAO 2019 presentations are as follows:

Title: Aura Biosciences

Presenter: Jay S. Duker, MD, New England Eye Center, Tufts Medical Center

Session: SYM22 The Innovators Symposium

Date and time: Sunday, October 13, 2019 from 2:47 – 2:54 PM PT

Location: Moscone Center, Esplanade Room

Title: Virus-Like Particles for Uveal Melanoma

Presenter: Amy C. Schefler, MD, Weill Cornell Medical College/Retina Consultants of Houston

Session: SYM50 Delivery of Therapeutics to the Posterior Ocular Segment

Date and time: Tuesday, October 15, 2019 from 9:35 – 9:45 AM PT

Location: Moscone Center, West 2002

Additional presentations taking place at other events in San Francisco around AAO 2019 include:

Event: Ophthalmology Innovation Summit (OIS) @ AAO

Title: Update on Aura Biosciences

Presenter: Elisabet de los Pinos, PhD, Chief Executive Officer of Aura Biosciences

Session: Innovation Showcase 1

Date and time: Thursday, October 10, 2019 from 8:40-8:47 AM PT

Location: Hilton San Francisco Union Square, 333 O’Farrell Street

Event: American Association of Ophthalmic Oncologists and Pathologists (AAOOP) 2019 Annual Meeting

Title: Study Update of an Ongoing Phase 1b/2 Open-label Clinical Trial of AU-011 for the Treatment of Small to Medium Choroidal Melanoma

Presenter: Abdhish Bhavsar, MD, The Retina Center

Date and time: Sunday, October 13, 2019

Location: Grand Hyatt San Francisco, 345 Stockton Street

About Choroidal Melanoma

Choroidal melanoma is a rare and aggressive type of eye cancer. Choroidal melanoma is the most common primary intraocular tumor in adults and develops in the uveal tract of the eye. No targeted therapies are available at present, and current radiotherapy treatments can be associated with severe visual loss and other long-term sequelae such as dry eye, glaucoma, cataracts and radiation retinopathy. The most common current treatment is plaque radiotherapy, which involves surgical placement of a radiation device on the exterior of the eye over the tumor. The alternative is enucleation, or total surgical removal of the eye. Choroidal melanoma metastasizes in approximately 50 percent of cases with liver involvement in 80-90% of cases and, unfortunately, metastatic disease is universally fatal (source: OMF). There is a very high unmet need for a new vision sparing targeted therapy that could enable early treatment intervention for this life-threatening rare disease given the lack of approved therapies, and the comorbidities of radioactive treatment options.

About Light-Activated AU-011

AU-011 is a first-in-class targeted therapy in development for the treatment of primary choroidal melanoma. The therapy consists of proprietary viral-like particle bioconjugates (VPB) that are activated with an ophthalmic laser. The VPBs bind selectively to unique receptors on cancer cells in the eye and are derived from technology originally pioneered by Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute (NCI), recipient of the 2017 Lasker-DeBakey Award. Upon activation with an ophthalmic laser, the drug rapidly and specifically disrupts the cell membrane of tumor cells while sparing key eye structures, which may allow for the potential of preserving patients’ vision and reducing other long-term complications of radiation treatment. AU-011 can be delivered using equipment commonly found in an ophthalmologist’s office and does not require a surgical procedure, pointing to a potentially less invasive, more convenient therapy for patients and physicians. AU-011 for the treatment of choroidal melanoma has been granted orphan drug and fast track designations by the U.S. Food and Drug Administration and is currently in clinical development.

On September 26, 2019, AbbVie Inc. ("AbbVie") reported sale of €1.4 billion aggregate principal amount of its senior notes, consisting of €750 million aggregate principal amount of 0.750% senior notes due 2027 and €650 million aggregate principal amount of 1.250% senior notes due 2031 (collectively, the "Notes") (Filing, 8-K, AbbVie, SEP 26, 2019, View Source [SID1234539811]). The offering of the Notes was made pursuant to a Prospectus Supplement, dated September 17, 2019 and filed with the Securities and Exchange Commission (the "SEC") on September 19, 2019 (the "Prospectus Supplement"), and the Prospectus dated September 13, 2018, filed as part of the shelf registration statement (File No. 333-227316) that became effective under the Securities Act of 1933, as amended, when filed with the SEC on September 13, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Notes are governed by an indenture, dated November 8, 2012 (the "Base Indenture"), by and between AbbVie and U.S. Bank National Association, as trustee (in such capacity, the "Trustee"), as supplemented by Supplemental Indenture No. 6, dated September 26, 2019 (the "Supplemental Indenture"), among AbbVie, the Trustee, Elavon Financial Services DAC, UK Branch, as paying agent (the "Paying Agent"), and U.S. Bank National Association, as transfer agent and registrar (in such capacity, the "Transfer Agent" and the "Registrar"). In connection with the issuance and sale of the Notes, AbbVie, the Trustee, the Paying Agent, the Transfer Agent and the Registrar also entered into an agency agreement, dated September 26, 2019 (the "Agency Agreement").

The Notes will mature on November 18 of the applicable year. The Notes are unsecured, unsubordinated obligations of AbbVie and will rank equally in right of payment with all of AbbVie’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations.

As previously disclosed, AbbVie intends to use the net proceeds from the offering of the Notes, together with cash on hand, (i) to redeem, satisfy and discharge or repay at maturity all of its 0.375% senior notes due 2019 in an aggregate outstanding principal amount of €1.4 billion, and to pay any premium and accrued interest in respect thereof, and/or (ii) for general corporate purposes.

Please refer to the Prospectus Supplement for additional information regarding the offering of the Notes and the terms and conditions of the Notes. The foregoing summary of the Notes does not purport to be complete and is qualified in its entirety by reference to the full text of (i) the Base Indenture attached as Exhibit 4.1 hereto; (ii) the Supplemental Indenture attached as Exhibit 4.2 hereto; (iii) the Agency Agreement attached as Exhibit 4.3 hereto; and (iv) the forms of the Notes attached as Exhibits 4.4 and 4.5 hereto.